Kymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024. In the quarter to June 2026, revenue grew 466.4%, EPS grew 34.7%, free cash flow grew 9.97% and total debt fell 62.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KYMR
Kymera Therapeutics, Inc. (KYMR) P/E ratio
Kymera Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. | n/m |
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | n/m |
| AXSM Axsome Therapeutics, Inc. compare | n/m |
| TGTX TG Therapeutics, Inc. compare | 17.8× |
| KRYS Krystal Biotech, Inc. compare | 38.3× |
| CAI Caris Life Sciences,�Inc. compare | 81.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 106× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)